Amneal Pharmaceuticals reported quarterly EPS of $0.27, beating the Zacks Consensus Estimate of $0.17 by $0.10 per share, and up from $0.21 a year ago. The result indicates a solid earnings beat and year-over-year improvement, which is modestly supportive for the stock.
Amneal Pharmaceuticals reported quarterly EPS of $0.27, beating the Zacks Consensus Estimate of $0.17 by $0.10 per share, and up from $0.21 a year ago. The result indicates a solid earnings beat and year-over-year improvement, which is modestly supportive for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
